Biotech | August 18, 2021
ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
_256_384.jpg)
The focus of this year’s challenge is to find solutions within Covid management and treatment of cardiovascular, renal, neuro, cancer and lung diseases
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
Subscribe To Our Newsletter & Stay Updated
